Latest Breaking News On - Silviu itescu - Page 3 : comparemela.com

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

11.03.2024 - NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA supports an accelerated approval pathway for . Seite 1

Silviu itescuMesoblast limited nasdaqRegenerative medicine advanced therapyBiologics license application

Biggest stock movers today: Crypto-linked stocks, MESO and more (NASDAQ:MESO)

Biggest stock movers today: Crypto-linked stocks, MESO and more (NASDAQ:MESO)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Silviu itescuMicrostrategy incorporatedMarathon digital holdingsBakkt holdingsBitdeer technologies holding companyDow jones industrial averageCoinbase globalRiot blockchainCipher miningStronghold digital miningHive blockchain technologiesBiologics license applicationOcular therapeutix

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSteve dabkowskiPaul hughesSilviu itescuPharmaceuticals coCorporate communications investorsMesoblast limited nasdaqDrug administrationResearch developmentMarrow transplant clinical trials networkNational institutes of healthAustralian securities exchangeMesoblast the companyChief executive silviu itescuUnited states food

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiSilviu itescuPaul hughesMesoblast limited nasdaqMesoblast the companyAustralian securities exchangeDrug administrationDrug designation programCorporate communications investorsJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiSilviu itescuPaul hughesDrug administrationCorporate communications investorsAustralian securities exchangeMesoblast the companyDrug designation programMesoblast limited nasdaqJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open